Earlier this week, Sandoz announced the launch of its adalimumab biosimilar, HYRIMOZ, in 40-mg doses for subcutaneous injection in either a syringe or prefilled pen, in Spain.   As we reported earlier, Sandoz previously launched HYRIMOZ in the UK in October 2018.  Samsung Bioepsis and Mylan also launched adalimumab biosimilars in Europe in October 2018.  According to the Center for Biosimilars press release, “[t]he market entry of biosimilar adalimumab could help Spain to reduce its pharmaceutical spending further if the country is able to mirror the successes of its EU counterparts.”